The 7 analysts offering 12-month price forecasts for Avita Therapeutics Inc have a median target of 10.64, with a high estimate of 60.00 and a low estimate of 6.27. The median estimate represents a -64.20% decrease from the last price of 29.72.
The current consensus among 8 polled investment analysts is to Buy stock in Avita Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share --
Reporting Date TBD
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.